Breast Cancer

There’s no moral to my story, except to say I’m grateful for good doctors and modern medicine.

I share how choosing what to do with my hair during treatment helped me reclaim control and redefine empowerment.

Dr. Erika Hamilton sat down for an interview with CURE’s editor-in-chief, Dr. Joshua K. Sabari.

From hair regrowth to safe pregnancy chemotherapy and new targeted therapies, these top five breast cancer stories of 2025 highlight patient care advances.

My dog Chloe had a lump that scared us, but it turned out to be a benign lipoma. Surgery went well, and she’s now fully healed and playful again.

Breast cancer survivors who continue to deal with high-risk factors in a remaining breast need to be proactive about medical protocols that fit a high-risk survivor’s needs.

Updated VIKTORIA-1 data show gedatolisib plus Faslodex, with or without Ibrance, improves progression-free survival in PIK3CA wild-type advanced breast cancer.

Cancer survivorship invites deeper questions about what we allow into our bodies, our homes, and the lives of those we love most.

Piqray plus Faslodex improved progression-free survival versus Faslodex alone in CDK4/6 inhibitor–pretreated, PIK3CA-mutated advanced breast cancer.

Dr. Roshani Patel answers questions from patients with breast cancer on Keytruda-induced colitis, sugar intake during chemo, and how to stay active.

Orserdu plus Verzenio or Afinitor was well tolerated and showed early signs of effectiveness in advanced ER-positive, HER2-negative breast cancer.

BOOG 13-08 shows skipping sentinel lymph node biopsy in patients 50+ with early-stage, hormone receptor–positive, HER2-negative breast cancer is safe.

Learn how diet and exercise impact breast cancer risk, while getting authoritative guidelines on plate balance, fiber goals, and complex vs. simple carbs.

Christmas is my favorite time of year. Since my child was diagnosed with cancer, however, the only gift I want is one more Christmas with her being here.

Trodelvy elicited fewer side effects that led to dose reduction compared with chemotherapy in previously untreated triple-negative breast cancer.

I have been diagnosed with breast cancer for the third time, and I find it interesting how the places where I seek support have changed over time.

Clinical trials give patients with metastatic breast cancer access to new treatments, all while being closely monitored and moving the landscape forward.

Trodelvy led to fewer side effects that required dose reductions or stopping treatment vs chemo among previously untreated triple-negative breast cancer.

At the 2025 SABCS, researchers presented findings with the potential to meaningfully affect breast cancer treatment and patient care.

Enhertu wins breakthrough therapy designation in some patents with HER2+ early breast cancer who have residual disease following neoadjuvant treatment.

Despite its vital function in many patients’ cancer journeys, palliative care is still the subject of several persistent myths and misconceptions.

Integrative oncology combines standard treatment with evidence-based complementary therapies to manage symptoms and empower patients.

DESTINY-Breast05 analyses show post neoadjuvant Enhertu improves invasive disease free survival compared with Kadcyla in patients with residual early stage breast cancer.

Losing an online friend to cancer reminded me that grief is real even across screens and that survivor guilt and gratitude can coexist in the same moment.

This patient guide explains triple-positive breast cancer, including treatment options, side effects and more to support informed conversations.